Good day, 360!
Here are our top 3 investing ideas today. And see our announcement below about the NEW Accelerator Course starting Monday. Be the best prepared trader on the Street!
BIOL – Up over 45% in pre after reporting earnings and issuing strong guidance
OKYO – Up over 18% in pre after Phase 2 success in dry eye disease treatment
FDX – FedEx up over 12% in pre after earnings beat, share buyback
Accelerator is Back!
Your chance to learn all our TOP strategies in a small-group environment starts THIS Monday – daily 12pm EST (times may vary).
All sessions recorded for on-demand learning – no excuses!
Contact Davis for more info: 1-800-585-4488 / [email protected]
BIOL – Up over 45% in pre after reporting earnings and issuing strong guidance
BIOLASE, Inc. (BIOL) together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally.
In the after-hours yesterday, the company reported full year 2023 earnings.
Net revenue for the year ended December 31, 2023, was $49.2 million, an increase of 1% compared to net revenue of $48.5 million a year prior.
Adjusted EBITDA for the year ended December 31, 2023, was a loss of $12.8 million vs Adjusted EBITDA loss of $20.1 million a year prior.
On December 31, 2023, the company had cash and cash equivalents of approximately $6.6 million. Following its February 2024 equity raise of an additional $7.0 million in gross proceeds, the Company believes it has sufficient liquidity to execute its near-term growth strategies and reach positive adjusted EBITDA for the full year 2024.
BIOL also issued strong guidance, expecting 2024 full-year net revenue to increase between 6% and 8% year over year to between $52 million and $53 million.
This reflects the continued adoption of lasers and consumables by the dental community, including general dentists, dental specialists, dental hygienists, and group practice entities (DSOs), offset by the challenging business environment.
The stock traded up over 45% in the pre-market after the earnings release yesterday.
$0.2350 was resistance in the after-hours and now become a potential support area.
Above it, targets to the upside are $0.2650 and then the pre-market high at $0.2767. Beyond that, $0.30, $0.3541 and $0.4490 come into play.
Below $0.2350, targets to the downside are $0.22, $0.2, $0.18 and then a gap fill at $0.15.
OKYO – Up over 18% in pre after Phase 2 success in dry eye disease treatment
OKYO Pharma Limited (OKYO) is a clinical-stage biopharmaceutical company that engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
This morning the company announced that its dry eye disease treatment OK-101 successfully achieved statistical significance for pain relief in its first-human Phase 2 trial.
Results included:
-
Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.
-
Conjunctival Staining improved as early as day 29 with a durable benefit throughout the trial.
-
Tear Film Break-up Time showed statistically significant improvement as early as day 15 with the benefit durable for the remainder of the trial.
The stock traded up over 18% in the pre-market after the news release.
The $1.98 area was support in the pre-market and now becomes potential resistance.
Above it, targets to the upside are $2.05, $2.15, $2.20 and then the pre-market high at $2.27. Beyond that, $2.70 and $3 come into play.
Below $1.98, targets to the downside are $1.90, $1.80, a gap fill at $1.76 and then $1.50.
Jeff Obliterated his $120k Goal… but he’s not satisfied. Here’s March:
*Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically.
And now he’s teamed up with TAIKU 🤺
FDX – FedEx up over 12% in pre after earnings beat, share buyback
FedEx Corporation (FDX) provides transportation, e-commerce, and business services in the United States and internationally.
In the after-hours yesterday, FDX reported Q4 earnings of $3.86 per share vs $3.46 expected.
Q4 revenue was $21.7 billion vs $22.05 billion estimate.
In addition, FedEx’s board approved a new $5 billion share buyback program.
The stock traded up over 12% in the pre-market after the earnings release.
$297.73 was resistance in the after-hours and will be an important level to watch.
Above it the first target for bulls is the $300 area. Beyond that, $305, $315 and then the all-time highs at $319.90 come into play.
Below $297.73, $295, $290, $285, $280 and $276 come into play.
Economic Calendar (EST)
👊 By the way, if you are NOT getting our mobile text alerts – text “RAGE” to 1-(888) 404-5747 to get all of our latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out!
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
DISCLAIMER To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
